PMI 06
Alternative Names: PMI-06Latest Information Update: 18 Jan 2024
At a glance
- Originator Precision Molecular
- Class Diagnostic agents; Imaging agents
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Non-small cell lung cancer
Most Recent Events
- 18 Jan 2024 PMI 06 is still in phase-I trials for Non-small cell lung cancer in USA (D and D Pharmatech pipeline, January 2024)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Cancer(Diagnosis) in USA
- 28 Sep 2021 Pharmacodynamics data from a preclinical trial in Cancer (Diagnosis) released by Precision Molecular